

Dear Valued Stakeholder,

At UCB, we are committed to discovering and providing innovative solutions that address significant unmet needs for people living with immunological diseases. As your partner, we also want to keep you informed on the most up-to-date information as it relates to our products that support your patients and the treatments they receive. This notice serves to provide you with the following information related to CIMZIA® (certolizumab pegol) required by a new Colorado state law, effective as of August 2, 2019:

- The wholesale acquisition cost, or WAC¹, of CIMZIA (the price at which UCB sells the product to wholesalers) is \$4,630.35² per two prefilled syringes. A one-month supply of CIMZIA is defined as 2x200mg/mL prefilled syringes. The WAC for the lyophilized powder (LYO) formulation is the same.
- There are no FDA approved generic products for CIMZIA from the same therapeutic class.

Your patients can expect the following pricing as it relates to CIMZIA:

- For commercially insured patients, about 60% of patients pay between \$0-\$200 per month for their CIMZIA prescription; the remaining 40% pay an average of \$550 per month.³
- With the CIMZIA Savings Card, a one-month supply of CIMZIA can cost as little as \$0. Learn more about the CIMplicity Savings Program at <https://www.cimzia.com/co-pay-program>.

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:

- Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
- Treatment of adults with moderately to severely active rheumatoid arthritis
- Treatment of adult patients with active psoriatic arthritis
- Treatment of adult patients with active ankylosing spondylitis
- Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
- Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Please see the full prescribing information provided by the UCB representative or visit www.CIMZIA.com.

UCB understands that the cost of medicines for patients can be complicated and difficult to determine. We encourage your patients to visit www.ucb-usa.com/Responsibility/Affordability to better understand what their out-of-pocket costs could be for UCB products. We also recommend patients call their insurance provider to discuss the benefits of their exact plan.

In addition, we have a dedicated team of compassionate and informed professionals who are trained to provide the answers you need. Please call ucbCARES® at 1-844-599-CARE (2273) if you or a patient have additional questions.

Kind regards,
UCB, Inc.

1 The WAC and generic names are provided to Colorado prescribers pursuant to Colorado Statute 12-42.5-308.

2 AnalySource. Accessed January 2020. Patients may have to pay a higher price than list due to additional pharmacy charges. Based on CIMZIA 2x200mg/mL

3 Symphony CIMZIA Patient Average Final OOP Cost per Script by Channel. (Jan 2018 – Oct 2018). Accessed January 2019.